Healthpeak Properties reports Q2 results on August 4 with options traders taking a sharply more bullish stance than at any point in recent memory — a striking contrast to a stock that has barely budged in a week.
The options signal is the standout heading into the print. The put/call ratio collapsed to 0.231 on July 31, more than four standard deviations below its 20-day average of 0.40 — the lowest reading of the past year, which bottomed at 0.195. That means call buyers are dominating the options market at an extreme level, even as the stock slipped 1% on the day and is down 2% on the week to $21.83. The divergence between bearish price action and bullish options flow is the clearest tension in the setup. Short interest, at 3.4% of the float, adds little to the story: borrow costs run at a negligible 0.48% and availability is deeply loose, meaning there is no meaningful squeeze pressure or short-side conviction driving the tape.
The analyst community has quietly turned more constructive over the past month. Multiple firms — including Mizuho (raising to $24), BMO Capital (lifting to $24), Wells Fargo (to $22), and UBS (to $21.50) — all raised price targets ahead of the report, bringing the consensus mean to $22.39 against a current price of $21.83. The exception is Morgan Stanley, which downgraded to Equal-Weight in June while also lifting its target to $22, a signal that some on the Street see the re-rating as largely complete. The bull case centers on Healthpeak's diversified ~700-property healthcare portfolio and new development projects running ~80% pre-leased with mid-7% stabilized yields. Bears point to lab tenant credit deterioration and weak life science leasing, which prompted at least one firm to slash FFOPS growth forecasts to near flat for 2026-2027.
Earnings history adds context the options market may be pricing. The two most recent prints both produced extraordinary moves — the stock jumped roughly 19-20% on the day and sustained gains of 18-21% over the following five days. The April 30 event was more modest at about 2.7% on the day but still delivered a 23% five-day move. That pattern of outsized post-earnings reactions explains why call buying would spike immediately before the August 4 release, even with the stock looking technically soft on the week.
The August 4 print is therefore less about whether Healthpeak's medical office assets are stabilizing and more about whether the life science segment can show any leasing recovery — the data point that separates a re-rating continuation from a reversal of this year's 40% gain.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
